Carmine Therapeutics, headquartered in Cambridge MA, is pioneering a new class of non-viral gene therapies based on red blood cell extracellular vesicles, combined with proprietary payloads. In June 2020, Carmine inked a research alliance with Takeda Pharmaceuticals worth up to $900 million to develop non-viral gene therapies for 2 targets. Carmine has also been named one of the FierceBiotech’s Fierce 15 Biotech companies of 2020 and was also awarded the Bristol-Myers Squibb "Golden Ticket". Carmine was founded in 2019 by EVX Ventures, Professors Harvey Lodish (Whitehead, MIT), Minh Le and Jiahai Shi. Professor Lodish, who was a founding member of several successful biotech companies that include Genzyme and Millennium Pharmaceuticals, is also Chair of the Scientific Advisory Board of Carmine.
For more information, visit www.carminetherapeutics.com
Media Relations
Media@carminetherapeutics.com
Investor Relations
Investors@carminetherapeutics.com
For more information, visit www.carminetherapeutics.com
Media Relations
Media@carminetherapeutics.com
Investor Relations
Investors@carminetherapeutics.com
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | EVX Ventur... | evx.ventur... |
Mentions in press and media 8
| Date | Title | Description |
| 14.10.2022 | StartUPDATES: New developments from healthcare startups | Memory Health, the only supplement patented for the prevention and/or treatment of neurodegenerative disease, has been proven in another independent clinical study, showing benefits in patients with mild-moderate Alzheimer’s disease. The st... |
| 13.10.2022 | Carmine Therapeutics Holds First Close of Series A Funding | Carmine Therapeutics, a Cambridge, MA-based EVX founded biotech company and emerging leader in non-viral gene therapies, held the first closing of its Series A financing. All existing investors including EVX Ventures, and Simcere Pharmaceut... |
| 05.05.2021 | Carmine Therapeutics appoints Don Haut as CEO | |
| 05.05.2021 | Carmine Therapeutics : appoints Don Haut as CEO | CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Carmine Therapeutics, Inc., an emerging leader in gene therapy, today announced that Don Haut, PhD has been appointed as its Chief Executive Officer, and member of the Board of Directors. Founde... |
| 05.05.2021 | Carmine Therapeutics appoints Don Haut as CEO | CAMBRIDGE, Mass., May 5, 2021 /PRNewswire/ -- Carmine Therapeutics, Inc., an emerging leader in gene therapy, today announced that Don Haut, PhD has been appointed as its Chief Executive Officer, and member of the Board of Directors. Founde... |
| 28.09.2020 | Carmine Therapeutics named as one of FierceBiotech's "Fierce 15" Biotech Companies of 2020 | |
| 28.09.2020 | Carmine Therapeutics : named as one of FierceBiotech's "Fierce 15" Biotech Companies of 2020 | CAMBRIDGE, Mass., Sept. 28, 2020 /PRNewswire/ -- Carmine Therapeutics announced today that it has been named by FierceBiotech as one of 2020's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnol... |
| 30.06.2020 | Carmine Therapeutics : and Takeda Collaborate to Discover and Develop Rare Disease Gene Therapies Using Novel Red Blood Cell Extracellular Vesicles Platform | CAMBRIDGE, Mass., June 30, 2020 /PRNewswire/ -- Carmine Therapeutics announced today that it has signed a research collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") to discover, develop and commercializ... |